Navigation Links
Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
Date:7/10/2008

TORONTO, July 10 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that it has entered into a exclusive distribution agreement in Russia with BB Medical for Spectral's Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. Under the terms of the agreement, BB Medical will market and sell EAA(TM) throughout the Russian Federation.

"BB Medical is a leading distributor of medical technologies in Russia. Their significant market reach in this region will help to strengthen our presence in yet another geographic territory - a key component in the global commercialization strategy for our EAA(TM) product," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Our distribution agreement with BB Medical in Russia is expected to be the first of several distribution agreements in new geographic territories. Ultimately, these alliances will drive the adoption of our unique product globally, both as a stand-alone product, and also in combination with therapeutics for the diagnosis, treatment and monitoring of patients with endotoxemia."

Spectral's distribution agreement with BB Medical is a result of the Company's expanded collaboration agreement with Toray Medical that was announced in May. Through this expanded agreement with Toray, Spectral may now access Toray's distributors in other geographic territories including China, India and Canada for the sales and promotion of EAA(TM).

About Spectral Diagnostics

Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed for this indication, Spectral is well-positioned to drive the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
3. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. Spectral appoints Anthony Bihl to Board of Directors
6. Spectral announces 2007 financial results
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
11. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... Conn. (PRWEB) , ... April 21, 2017 , ... ... (CI) and Webster Bank, today announced first round funding to three startups through ... provide early-stage financial support to new business startups affiliated with UConn. , The ...
(Date:4/20/2017)... ... April 20, 2017 , ... As part of ... explore challenging patient cases when screening for direct oral anticoagulant. When patients taking ... need for bridging parental anticoagulation especially for those at high risk of thrombosis ...
(Date:4/20/2017)... , ... April 20, 2017 , ... NetDimensions appoints Bill ... , With over 20 years of experience in the learning technologies industry, Mastin joins ... company within Learning Technologies Group plc (LTG). At LEO, Mastin served as SVP of ...
(Date:4/20/2017)... Koert van Mensvoort - founder of the Next Nature Network and ... has written a ,Letter to Humanity, in support of International Earth ... and victim to its own technology, but to employ technology to enhance our ... ... of the Next Nature Network and Fellow of ‘Next Nature’ at the University ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):